within Pharmacolibrary.Drugs.C_CardiovascularSystem.C02C_AntiadrenergicAgentsPeripherallyActing.C02CC04_Debrisoquine;

model Debrisoquine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.7,
    Cl = 1.6666666666666665e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.145,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Debrisoquine</td></tr><tr><td>ATC code:</td><td>C02CC04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>145</td><td>L</td></tr>
    <tr><td>clearance:</td><td>100</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Debrisoquine is a sympatholytic antihypertensive agent formerly used for the treatment of hypertension. It is recognized mostly for its use as a probe drug for CYP2D6 pharmacogenetic phenotyping. As of now, debrisoquine is rarely used clinically.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Sjöqvist, F, &amp; Bertilsson, L (1984). Clinical pharmacology of antidepressant drugs: pharmacogenetics. <i>Advances in biochemical psychopharmacology</i> 39 359–372. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6380229/\">https://pubmed.ncbi.nlm.nih.gov/6380229</a></p></li><li><p>Mahgoub, A, et al., &amp; Smith, RL (1977). Polymorphic hydroxylation of Debrisoquine in man. <i>Lancet (London, England)</i> 2(8038) 584–586. DOI:<a href=\"https://doi.org/10.1016/s0140-6736(77)91430-1\">10.1016/s0140-6736(77)91430-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/71400/\">https://pubmed.ncbi.nlm.nih.gov/71400</a></p></li><li><p>Boriani, G, et al., &amp; Magnani, B (1990). [Determination of oxidative phenotype in a sample population and correlation with the pharmacokinetics of propafenone]. <i>Cardiologia (Rome, Italy)</i> 35(2) 163–169. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2208201/\">https://pubmed.ncbi.nlm.nih.gov/2208201</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C02CC04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Debrisoquine;
